Z Stock Recent News
Z LATEST HEADLINES
First, it's hard to get too negative when capital expenditures for companies building out AI infrastructure are running near $400 billion annualized, growing roughly 50% Y/Y. These are not small numbers and they've already influenced economic activity across sectors.
Z's Q2 revenues jump 14.5% to beat estimates, but EPS misses the same as rising costs pressure margins despite strong rental growth.
Zillow Group, Inc. (NASDAQ:Z ) Q2 2025 Earnings Conference Call August 6, 2025 5:00 PM ET Company Participants Bradley Allen Berning - Vice President of Investor Relations Jeremy Hofmann - Chief Financial Officer Jeremy Wacksman - CEO & Director Conference Call Participants Andrew M. Boone - Citizens JMP Securities, LLC, Research Division Bradley D.
Zillow (Z) came out with quarterly earnings of $0.4 per share, missing the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.39 per share a year ago.
Zillow beat estimates for its second quarter with $655 million in revenue, up 15% year-over-year.
Real estate player CoStar, parent of Homes.com and Apartments.com, is suing Zillow, claiming the online real estate marketplace is using tens of thousands of its copyrighted photographs to prop up its business.
CoStar files lawsuit against Zillow claiming systematic copyright infringement of photographs distributed across Zillow's network. Many of the images have the CoStar watermark.
This story originally appeared on Real Estate News.
Zillow was sued on Wednesday by real estate information provider CoStar Group , which accused the largest U.S. online real estate portal of publishing at least 46,979 copyrighted photos without permission.
SEATTLE , July 29, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines in oncology, today announced positive written feedback from the U.S. Food and Drug Administration (FDA) regarding the company's proposed dose optimization trial of (Z)-endoxifen for the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. With the FDA's feedback, Atossa is energized and moving quickly to advance (Z)-endoxifen in metastatic breast cancer.